Antibiotic treatment for septic shock is generally prescribed on an empirical basis using broad-spectrum antibiotics. Molecular diagnostic techniques can detect the presence of microbial DNA in blood within a few hours and facilitate early, targeted treatment. The aim of this study was to evaluate the economic impact of a real-time polymerase chain reaction technique, LightCycler SeptiFast (LSC), in patients with sepsis.
A cost-minimisation study was carried out in patients admitted with a diagnosis of severe sepsis or septic shock to the intensive care unit of a university hospital. The stay in the intensive care unit, hospital admission, 28-day and six-month mortality, and the economic cost of the clinical process were also evaluated. The study involved 48 patients in the LSC group and 54 patients in the control group.
The total cost was €42,198 in the control group versus €32,228 in the LCS group with statistically significant differences (P <0.05), giving rise to an average net saving of €9970 per patient. The mortality rate was similar in both groups.
The main finding of this study was the significant economic saving afforded by the use of the LCS technique, due to the shortening of intensive care unit stay and the use of fewer antibiotics.
AngusD.C., Linde-ZwirbleW.T., LidickerJ., ClermontG., CarcilloJ., PinskyM.R.Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med2001; 29: 1303–1310.
2.
AnnaneD., AegerterP., Jars-GuincestreM.C., GuidetB.Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med2003; 168: 165–172.
3.
PadkinA., GoldfradC., BradyA.R., YoungD., BlackN., RowanK.Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med2003; 31: 2332–2338.
4.
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.Am J Respir Crit Care Med2005; 171: 388–416.
5.
KollefM.H., ShermanG., WardS., FraserV.J.Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest1999; 115: 462–474.
6.
SchrammG.E., JohnsonJ.A., DohertyJ.A., MicekS.T., KollefM.H.Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med2006; 34: 2069–2074.
7.
HarbarthS., GarbinoJ., PuginJ., RomandJ., LewD., PittetD.Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med2003; 115: 529–535.
8.
AndradeS.S., BispoP.J.M., GalesA.C.Advances in the microbiological diagnosis of sepsis. Shock2008; 30(Suppl 1): 41–46.
9.
LehmannL.E., AlvarezJ., HunfeldK-P, GoglioA., KostG.J., LouieR.F.Potential clinical utility of polymerase chain reaction in microbiological testing for sepsis. Crit Care Med2009; 37: 3085–3090.
10.
RegueiroB.J., Varela-LedoE., Martinez-LamasL., Rodriguez-CalvinoJ., AguileraA., SantosA.Automated extraction improves multiplex molecular detection of infection in septic patients. PLoS One2010; 5: e13387.
11.
LehmannL.E., HerpichboehmB., KostG.J., KollefM.H., StuberF.Cost and mortality prediction using polymerase chain reaction pathogen detection in sepsis: evidence from three observational trials. Crit Care2010; 14: R186.
12.
FangC., OteroH.J., GreenbergD., NeumannP.J.Cost-utility analyses of diagnostic laboratory tests: a systematic review. Value Health2011; 14: 1010–1018.
13.
Diagnostics Assessment Programme manual.National Institute for Health and Clinical Excellence.Manchester2011.
14.
DellingerR.P., LevyM.M., CarletJ.M., BionJ., ParkerM.M., JaeschkeR.Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med2008; 36: 296–327.
15.
DellingerR.P., CarletJ.M., MasurH., GerlachH., CalandraT., CohenJ.Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med2004; 30: 536–555.
16.
LevyM.M., FinkM.P., MarshallJ.C., AbrahamE., AngusD., CookD.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med2003; 31: 1250–1256.
17.
LehmannL.E., HunfeldK-P, EmrichT., HaberhausenG., WissingH., HoeftA.A multiplex real-time PCR assay for rapid detection and differentiation of 25 bacterial and fungal pathogens from whole blood samples. Med Microbiol Immunol2008; 197: 313–324.
18.
McGuireA.Theoretical concepts in the economic evaluations of health care. In: DrummondM., McGuireA., eds. Economic evaluation in health care. Merging theory with practice. Oxford: Oxford University Press2001.
19.
DrummondM.F., O'BrienB., StoddartG.L., TorranceG.W.Cost analysis. In: DrummondM.F. ed. Methods for the economic evaluation of health care programmes.Oxford: Oxford University Press1997. p. 52–95.
20.
GoldM.R., SiegelJ.E., RussellL.B., WeinsteinM.C.Cost-effectiveness in health and medicine.New York: Oxford University Press1996.
21.
BriggsA.H., WonderlingD.E., MooneyC.Z.Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ1997; 6: 327–340.
22.
MacLarenR., BondC.A., MartinS.J., FikeD.Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med2008; 36: 3184–3189.
23.
SacristanJ.A., PrietoL., HueteT., ArtigasA., BadiaX., ChinnC.[Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain]. Gac Sanit2004; 18: 50–57.
24.
van den BergheG., WoutersP., WeekersF., VerwaestC., BruyninckxF., SchetzM.Intensive insulin therapy in the critically ill patients. N Engl J Med2001; 345: 1359–1367.
25.
RiversE., NguyenB., HavstadS., ResslerJ., MuzzinA., KnoblichB.Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med2001; 345: 1368–1377.
LeoneM., MartinC.How to break the vicious circle of antibiotic resistances?Curr Opin Crit Care2008; 14: 587–592.
28.
EagyeK.J., NicolauD.P., LockhartS.R., QuinnJ., DoernG., GallagherG.A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004. Ann Clin Microbiol Antimicrob2007; 6: 11–17.
